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The inherent disadvantages of using granulocyte colony-stimulating factor (G-CSF) for
hematopoietic stem cell (HSC) mobilization have driven efforts to identify alternate strategies
based on single doses of small molecules. Here, we show targeting a9b1/a4b1 integrins
with a single dose of a small molecule antagonist (BOP (N-(benzenesulfonyl)-L-prolyl-L-O-
(1-pyrrolidinylcarbonyl)tyrosine)) rapidly mobilizes long-term multi-lineage reconstituting
HSC. Synergistic engraftment augmentation is observed when BOP is co-administered with
AMD3100. Impressively, HSC in equal volumes of peripheral blood (PB) mobilized with this
combination effectively out-competes PB mobilized with G-CSF. The enhanced mobilization
observed using BOP and AMD3100 is recapitulated in a humanized NODSCIDIL2Rg /
model, demonstrated by a signiﬁcant increase in PB CD34þ cells. Using a related ﬂuorescent
analogue of BOP (R-BC154), we show that this class of antagonists preferentially bind human
and mouse HSC and progenitors via endogenously primed/activated a9b1/a4b1 within the
endosteal niche. These results support using dual a9b1/a4b1 inhibitors as effective, rapid and
transient mobilization agents with promising clinical applications.
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T
he transplant of mobilized peripheral blood (PB)
hematopoietic stem cell (HSC) into patients undergoing
treatment for blood diseases has essentially replaced
traditional bone marrow (BM) transplants. Current clinical
practice for HSC mobilization is achieved with an extended
course of recombinant granulocyte colony-stimulating factor
(G-CSF), which stimulates the production of proteases that cleave
many interactions including CXCR4/SDF-1 (refs 1,2).
However, G-CSF-based mobilization requires multiple doses
over a number of days, is known to alter the function of the
HSC niche as well as bone formation3, can cause bone pain and
spleen enlargement and on rare occasions G-CSF results in
splenic rupture, myocardial infarction or cerebral ischaemia
(reviewed in refs 4,5). These inherent disadvantages of G-CSF
have driven efforts to identify alternate mobilization strategies
based on the use of single doses of small molecules6,7.
For example, the Food and Drug Administration (FDA)-
approved chemokine (C-X-C motif) receptor 4 (CXCR4)
antagonist AMD3100 (Plerixafor; MozobilTM) has been shown
to rapidly mobilize HSC with limited toxicity issues8,9.
Nevertheless, clinical mobilization with AMD3100 is only
effective in combination with G-CSF and the search for rapid,
selective and G-CSF-independent mobilization regimes remains a
topic of interest.
HSC regulation and retention within the BM stem cell niche is
mediated through multiple interactions between HSC surface
receptors and their respective ligands expressed or secreted by
surrounding cells: including osteoblasts, sinusoidal endothelial
cells and perivascular cells (reviewed in refs 10–12). Functional
analysis of BM HSC demonstrate those with the greatest
hematopoietic potential, which preferentially localize in the
endosteal region (B12 cell diameters from the bone surface13).
Of note, HSC identical for the classic LinSca-1þ ckitþ
CD150þCD48 phenotype, but isolated from endosteal BM
have greater homing potential and enhanced long-term,
multi-lineage hematopoietic reconstitution relative to HSC
isolated from the central medullary cavity14. Thus, the
therapeutic targeting of endosteal HSC for mobilization should
provide better transplant outcomes.
Both a4b1 (VLA-4) and a9b1 expressed by HSC have been
implicated in niche retention through binding to thrombin-cleaved
osteopontin (trOpn) in the endosteal region15,16 and vascular cell
adhesion molecule 1 (VCAM-1) expressed by BM stromal cells17.
While the role of a9b1 in HSC mobilization is unknown, the down
regulation of Opn using non-steroidal anti-inﬂammatory drugs as
well as targeting a4 (for example, a4b1 antagonist BIO5192) with
or without AMD3100 or G-CSF have validated trOpn/VCAM-1
binding to integrins as effective targets for HSC mobilization6,18–
20. Nevertheless, the lack of suitable blocking antibodies and
selective small molecules directed towards a9b1 has hindered our
understanding of a9b1-dependent HSC mobilization. Furthermore,
the speciﬁc cell types targeted for mobilization, as well as their
location in BM have not previously been investigated.
We recently developed a ﬂuorescent integrin antagonist, R-BC154
(ref. 21) based on the small molecule N-(benzenesulfonyl)-L-prolyl-
L-O-(1-pyrrolidinylcarbonyl)tyrosine22 (BOP), which we previously
demonstrated to bind effectively to a9b1 and a4b1 integrins in the
presence of divalent metal cations21. Based on the interaction
between a9b1/a4b1 and trOpn being restricted to endosteal BM, we
postulated that this family of compounds would target potent
endosteal HSC for mobilization. Herein, we show that R-BC154 and
BOP preferentially bind endosteally located human and murine
BM HSC and progenitors in vitro and in vivo and this binding is
highly dependent on a9b1. Consequently, administration of a
single dose of BOP results in the rapid and preferential mobilization
of HSC and progenitors in mice and humanized mouse models,
and is synergistically augmented when used in combination with
AMD3100. When BOP is co-administered with AMD3100, greater
mobilization is observed relative to AMD3100 in combination with
the selective a4b1 antagonist BIO5192, identifying an active role for
a9b1 in small molecule-mediated mobilization. A single dose of BOP
and AMD3100 is also shown to mobilize HSC with greater
long-term repopulation potential than HSC following a 4-day
G-CSF regime. Together, our results show therapeutic targeting
of BM HSC using a9b1/a4b1 inhibitors either alone or in
combination with AMD3100 offers promising alternatives to
current mobilization strategies.
Results
R-BC154 and BIO5192 reveals speciﬁc binding to HSC a9b1.
To assess the speciﬁc targeting of a9b1 on HSC by small molecule
antagonists, we developed an in vitro assay using the selective and
potent (Kdo10 pM) a4b1 antagonist BIO5192 (ref. 23), the dual
a9b1/a4b1 antagonist BOP and its ﬂuorescent analogue R-BC154
(Fig. 1a); which we have demonstrated to efﬁciently bind to
both human21 and murine (Supplementary Fig. 1a) a9b1 and
a4b1 integrins in a divalent metal cation-dependent manner.
This is in contrast to BIO5192, which binds a4b1 in the presence
and absence of divalent metal cations23. The co-labelling of
both human and murine a9b1/a4b1 with R-BC154 and excess
BIO5192 allowed the speciﬁc detection of binding to a9b1
(Fig. 1b,c). In contrast, R-BC154 labelling in combination with
excess BOP completely inhibited R-BC154 binding to both
human and murine a9b1/a4b1 integrins (Fig. 1b,c). Given
the ubiquitous expression of a4b1 on all hematopoietic cells, the
combination of R-BC154 with BIO5192 provides a convenient
method of measuring speciﬁc binding to a9b1 on hematopoietic
stem and progenitors.
R-BC154 and BOP preferentially bind HSC and progenitors.
We have previously demonstrated human HSC express a9b1 and
its interaction with trOpn regulates HSC quiescence16. To
determine whether dual a9b1/a4b1 antagonists bind human HSC
via a9b1, R-BC154 binding to cord blood (CB) mononuclear cells
(MNC) was assessed and shown to be divalent cation and dose
dependent, and saturable (Fig. 1d). Analysis of CB HSC
(CD34þCD38 ), progenitors (CD34þCD38þ ) and lineage-
committed cells (CD34CD38þ ) (Fig. 1e) revealed high
R-BC154 binding to HSC and progenitors, but only modest
binding to committed cells in the presence of 1mM Ca2þ /Mg2þ
(Fig. 1f). Furthermore, co-incubation of these populations with
R-BC154 in combination with BIO5192 demonstrated partial
inhibition of R-BC154 binding to HSC and progenitors (reﬂective
of binding via both a9b1 and a4b1) and complete inhibition of
binding to lineage-committed cells (reﬂective of binding only via
a4b1) (Fig. 1f). In contrast, as BOP effectively binds both a9b1 and
a4b1, its addition resulted in complete inhibition of R-BC154
binding to all cell populations (Fig. 1f). Together, these data
demonstrate a signiﬁcant proportion of R-BC154 binding to HSC
and progenitors via a9b1, while binding to committed cells is
mediated exclusively through a4b1 (Fig. 1g).
In addition, R-BC154 efﬁciently bound HSC and progenitors
isolated from human BM in the presence of Ca2þ /Mg2þ (Fig. 1h)
and similarly to that evident with CB cells, the majority of this
binding was via a9b1 compared with committed cells that
primarily bound via a4b1 (Fig. 1i). These data are consistent with
the high a9b1 expression evident on human BM HSC and
progenitors (Fig. 1j).
R-BC154 binding to human HSC was further evaluated using
humanized NODSCIDIL2Rg / (huNSG) mice (Supplementary
Fig. 1b)24. R-BC154-bound human BM-committed cells, progenitors
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Figure 1 | R-BC154 and BOP preferentially bind human and murine HSC and progenitors in a divalent cation and integrin-dependent manner.
(a) Chemical structure of R-BC154 (1) and BOP (2). (b) Use of R-BC154, BOP and BIO5192 to demonstrate speciﬁc detection of binding to a9 (grey) in
human and (c) murine overexpressing cell lines (LN18 and CHO respectively) compared with a4 (black) in the presence of 1mM Ca2þ/Mg2þ n¼ 3 and is
representative of at least two independent experiments. (d) Dose response of R-BC154 binding to human CB MNC. n¼ 3 and is representative of two
independent experiments. Binding in the presence of cations is signiﬁcantly greater at all concentrations except 0 nM (Po0.005). (e) Representative
populations of CB HSC (CD34þCD38 ), progenitors (CD34þCD38þ ) and committed cells (CD34CD38þ ). (f) R-BC154 binding to CB MNC
committed cells, progenitors and HSC in the presence of 1mM Ca2þ/Mg2þ alone, or in combination with BOP or BIO5192. Data are representative of
three individual samples. US, unstained. a9—speciﬁc binding via a9b1, a4—speciﬁc binding via a4b1. (g) Speciﬁc binding of R-BC154 binding to a9b1 on
CB-committed cells (CC), progenitors (prog) and HSC. n¼ 3 (h) R-BC154 binding to human BM (huBM). Data are representative of three individual
samples. (i) Speciﬁc binding of R-BC154 to huBM a9b1. n¼ 3 (j) a9b1 expression on huBM progenitors and HSC (grey solid line, dashed line IgG1 isotype
control). Data are representative of three individual samples. (k) R-BC154 binding to humanized NSG (huNSG) BM. Data are representative of three
individual samples. (l) Speciﬁc binding of R-BC154 to huNSG BM a9b1. n¼ 3. (m) a9b1 expression on huNSG BM progenitors and HSC (grey solid line,
dashed line IgG1 isotype control). Data are representative of three individual samples. (n) R-BC154 binding to mu BM-committed cells, progenitors
(LinSca-1þc-kitþ ; LSK) and HSC (LSKCD150þCD48 ; LSKSLAM). Data are representative of three individual samples. (o) Speciﬁc binding of R-BC154
to mu BM a9b1. n¼ 3. CB CD34þ cells were transplanted into 6.5 week old male (n¼ 1) and female (n¼ 2) NSG mice (k,l). Around 7–8-week-old female
C57 mice were used for n and o. All data are mean±s.e.m. Analysis using one-way ANOVA (g,i,l,o) or two-way ANOVA (d), *Po0.05, **Po0.01,
***Po0.005, ****Po0.001.
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and HSC in the presence of Ca2þ /Mg2þ (Fig. 1k), but signiﬁcant
binding through a9b1 only occurred on HSC (Fig. 1l), which is
consistent with a9b1 expression being restricted to HSC (Fig. 1m).
In contrast, a4b1 was highly expressed on all three populations
(Supplementary Fig. 1c).
The ubiquitous expression of a4b1 on hematopoietic cells,
together with the restricted expression of a9b1 on HSC resulted in
an additive R-BC154 binding to HSC relative to progenitors and
committed cells (Supplementary Fig. 1d). Furthermore, single-cell
correlation analysis of scaled ﬂuorescence intensity values
for both R-BC154 binding to a9b1 in the presence of BIO5192
(to prevent any binding to a4b1) and a9b1 expression
(Supplementary Fig. 1e) shows a positive correlation in speciﬁc
binding of BOP to a9b1 on CB HSC with the expression of a9b1.
Together these data highlight the potential for human HSC
and/or progenitors to be targeted in preference to lineage-
committed cells using selective a9b1 antagonists.
Consistent with their human counterparts, analysis of R-BC154
binding to murine BM progenitors and HSC (Supplementary
Fig. 1f; Fig. 1n) revealed this to be cation (Supplementary Fig. 1g)
and a4/a9 (Supplementary Fig. 1h) dependent. Similarly to their
human counterparts, a signiﬁcant proportion of R-BC154 binding
to murine HSC was via a9b1 whereas binding to lineage-
committed cells was mediated primarily through a4b1 (Fig. 1o).
R-BC154 binding to murine BM progenitors and HSC was
conﬁrmed in vivo following subcutaneous administration of
R-BC154, with similar levels of binding to that observed in the
presence of exogenous Ca2þ /Mg2þ in vitro (Supplementary
Fig. 1i). The speciﬁc and reversible nature of R-BC154 binding
in vivo was conﬁrmed by efﬁcient displacement of in situ-bound
R-BC154 with the addition of excess competing BOP in vitro
(Supplementary Fig. 1j,k).
Endosteal HSC a9b1/a4b1 are endogenously activated. To date, a
number of studies have demonstrated integrins adopt three
conformational states: (1) inactive or low afﬁnity; (2) activated
(primed) or high afﬁnity; and (3) ligand occupied (reviewed in
ref. 25). This integrin activity is regulated via both inside-out
activation or outside-in activation26,27. In the BM stem cell niche,
the regulation of integrins on HSC is complex and has not been
accurately mimicked or recapitulated in vitro28. In addition, we
have previously shown that the region in which BM HSC reside
has a profound inﬂuence on their function, with HSC isolated from
the endosteal region having higher hematopoietic potential than
their central counterparts14,29. Whilst the mechanisms of these
differences remain poorly understood, signiﬁcant differences in
cellular and extracellular matrix molecules have been described in
different BM regions, many of which are likely to play a role30,31.
To determine whether a9b1/a4b1 integrins expressed by HSC
and progenitors within different regions of BM are differentially
primed/activated in situ, R-BC154 binding to endosteal and central
human BM HSC in huNSG mice was assessed (Fig. 2a). Endosteal
huCD34þ cells isolated from huNSG mice injected
subcutaneously with R-BC154 exhibited signiﬁcantly greater
binding than their central counterparts (Fig. 2b). In addition,
when huNSG BM cells from either endosteal or central
regions were labelled with R-BC154 in vitro in the absence of
exogenous cations, only binding to endosteal progenitors and
HSC was detected (Fig. 2c,d) although no differences in the
expression of a9b1 or a4b1 was evident on cells from the central or
endosteal BM regions (Supplementary Fig. 1l). Similarly,
R-BC154 binding in the absence of exogenous cations was also
restricted to murine HSC and progenitors harvested from
endosteal BM (Fig. 2e,f). These data demonstrate that integrins
expressed by endosteal stem and progenitors are endogenously
activated or primed and remain in this ligand-binding receptive
conformational state post harvest.
Divalent metal cations are concentrated at the endosteum. The
precise mechanisms leading to integrin priming/activation in vivo
remain unclear, although previous studies have demonstrated
activation of a4 in vitro via a number of mechanisms including
ligand binding32,33, divalent cations34 and cytokines35,36.
In the in vivo endosteal BM region, differences in a9b1/a4b1
activation states may in part be due to the binding of their
ligands, such as trOpn, which we have previously demonstrated
to be restricted to this region16. However, the endogenously
primed integrin activation state may also be due to the higher
concentrations of divalent metal cations (for example, Ca2þ ,
Mg2þ and Mn2þ ) present in endosteal BM in situ. Elemental
mapping of non-decalciﬁed cross-sections of diaphyseal
murine femoral BM using X-ray ﬂuorescence microscopy
(XFM) was used to assess calcium content. Areas of
cortical bone and cells were veriﬁed by bright-ﬁeld microscopy
and could be distinguished by XFM based on their elastic,
Compton and calcium scattering proﬁles. Speciﬁcally, bone is
elastichigh/Comptonhigh/calciumhigh while marrow cells are
elasticlow/Comptonhigh/calciumlow (Fig. 2g). Measurement of
calcium in BM demonstrated a distinct concentration gradient,
emanating from the endosteal bone/BM interface and decreasing
towards the central BM and central vein (Fig. 2g,h). XFM was
unable to distinguish magnesium due to strong absorption of Mg
K shell ﬂuorescence by the air path and the intense Fe K shell
ﬂuorescence severely limited sensitivity to manganese.
In addition, BM magnesium, manganese and calcium content
were assessed using inductively coupled plasma mass spectro-
metry (ICP-MS), which revealed a greater abundance of calcium
and manganese in endosteal extracellular ﬂuid relative to central
BM (Fig. 2i) as well calcium, magnesium and manganese bound
to the cellular membranes of endosteal cells relative to central
BM cells (Fig. 2j). To ensure the accuracy of these measurements,
the proportion of each cation that was mechanically released
by grinding the bone to isolate the endosteal cells was measured
and subtracted from the raw extracellular measurements
(Supplementary Fig. 2a). Furthermore, the ability of the
combination of these mechanically released cation concentrations
to activate integrins on central BM cells was assessed by
measuring the binding of R-BC154 to progenitors and HSC after
treatment with the endosteal extracellular ﬂuid (as assessed in
Fig. 2i). As a further control, the measured concentrations of
‘mechanically released’ cations were added to central marrow cells
and their ability to activate integrins resulting in the binding of
R-BC154 assessed. No evidence of R-BC154 was detected under
any of these conditions (Supplementary Fig. 2b) conﬁrming the
endogenous activation of integrins before cell isolation.
In contrast, the concentrations of these three cations located
intracellularly was equivalent in cells located in the endosteal and
central BM regions (Fig. 2k). Collectively, these data demonstrate
higher concentrations of divalent metal cations required for
integrin function within endosteal BM. Together with extracellular
matrix (ECM) ligands such as trOpn or VCAM-1 and other
cytokines, this would result in integrins on endosteal HSC being
maintained in an activated/primed/ligand-occupied conforma-
tional binding state, thus potentially forming the mechanism
underpinning preferential targeting of endosteal HSC and
progenitors by integrin antagonists such as R-BC154 and BOP.
BOP rapidly and preferentially mobilizes HSC and progenitors.
As BOP rapidly and preferentially binds BM HSC, the ability of
BOP to mobilize HSC to the PB was initially analysed in a dose and
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time response assay and by quantifying progenitors (LSK)
and HSC (LSKSLAM) post-subcutaneous BOP administration
(Fig. 3a,b). The administration of BOP resulted in a rapid,
signiﬁcant and dose-dependent increase in PB progenitors and
HSC (Fig. 3a), which peaked 60min after a single dose (Fig. 3b)
and returned to baseline within 4 h post administration
(Supplementary Fig. 2c,d). Furthermore, whilst there was an initial
signiﬁcant increase in total PB lymphocytes, these also decreased to
baseline by 18h (Supplementary Fig. 2e).
In contrast, R-BC154, although capable of efﬁciently binding
BM progenitors (LSK cells) and HSC (LSKSLAM cells) in vitro
(Supplementary Fig. 1h), only resulted in moderate increase in PB
progenitors and HSC when administered in vivo (Supplementary
Fig. 2f). The reduced in vivo efﬁcacy of R-BC154 relative to BOP
is most likely the result of the former having lower binding
afﬁnities as determined by association and dissociation kinetics
studies in vitro21,22 and thus reduced inhibitory potency towards
integrin-dependent adhesive interactions.
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Figure 2 | R-BC154 targets HSC and progenitors via endogenously activated/primed a4/a9 integrins in endosteal BM. (a) Schematic of central BM
(cBM; blue) and endosteal BM (eBM; orange). (b) in vivo R-BC154 binding to huNSG central (blue) and endosteal (orange) BM huCD34þ cells compared
with uninjected control (grey). Data are representative of three animals. (c) In vitro R-BC154 binding to huNSG central and endosteal BM progenitors
(CD34þCD38þ cells) and HSC (CD34þCD38 cells) in the absence of exogenous cations compared with uninjected control. Data are the
representative of three samples. (d) Quantiﬁed R-BC154 binding from c, n¼ 3. (e) In vitro R-BC154 binding to murine central and endosteal BM progenitors
(LSK cells) and HSC (LSKSLAM cells) in the absence of exogenous cations compared to uninjected control. Data are representative of 410 samples.
(f) Quantiﬁed R-BC154 binding from e, n¼ 5. (g) Representative XFM images depicting the elastic scattering, Compton scattering and calcium distribution
proﬁle of a diaphyseal cross-section of non-decalciﬁed murine femur. White arrow depicts calcium gradient radiating away from the endosteal surface
(red dotted line). The hashed white line atB100 mm from the bone surface represents the interface between eBM and cBM. (h) Calcium content across
representative line a to b in g, which begins B20mm and extends to B220mm from the endosteal surface. Data are expressed as arbitrary units (a.u.)
n¼ 10 different lines a to b. Representative of three animals. (i) Quantitative analysis of calcium, magnesium and manganese in murine BM central and
endosteal extracellular ﬂuid, (j) membrane bound (k) and intracellular. n¼ 3. The endosteal extracellular component has been corrected for mechanically
caused release (Supplementary Fig. 2a). CB CD34þ cells were transplanted into 9-week-old female NSG mice (b–d). Around 7–8-week-old female mice
were used for e–h. All data are mean±s.e.m. Analysis using t-test, *Po0.05, ***Po0.005, ****Po0.001.
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Using BOP and targeting CXCR4 enhances HSC mobilization.
Previous studies have shown that the inhibition of a4b1 results in
additive/synergistic HSC mobilization when used in combination
with CXCR4 antagonists such as AMD3100 (refs 6,37,38).
Administration of AMD3100 resulted in similar increase in
WBC counts (7.8±1.5 106ml 1) relative to BOP
(7.0±0.8 106ml 1) and comparable increases in the
proportion of progenitors (LSK cells) in the PB (Fig. 3c). How-
ever, BOP resulted in a signiﬁcantly greater increase in
the proportion of HSC (LSKSLAM cells) in the PB relative
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to AMD3100 (Fig. 3d; Po0.05), suggesting AMD3100
predominantly mobilizes progenitors in addition to some HSC,
while BOP predominantly mobilizes HSC in addition to some
progenitors. In addition, the combination of BOP and AMD3100
synergistically mobilized WBC (16.4±1.9 106ml 1), progeni-
tors and HSC compared with BOP or AMD3100 alone (Fig. 3e).
Interestingly, signiﬁcantly greater binding of BOP to endosteal
LSK was observed relative to their central counterparts in vivo
(Supplementary Fig. 2g), further supporting the data obtained
using R-BC154 (Fig. 2b–f).
Inhibiting a9b1, a4b1 and CXCR4 enhances HSC mobilization.
To determine whether co-inhibition of a9b1 provides a
mobilization advantage over the inhibition of a4b1 alone or in
combination with CXCR4, the selective a4b1 inhibitor BIO5192
was used. BIO5192 has been reported to mobilize CFUs and
long-term repopulating HSC with and without AMD3100 (ref. 6)
but the speciﬁc cell types mobilized were not investigated.
Intravenous administration of BIO5192 resulted in only moderate
increase in WBC counts (Supplementary Fig. 2h), progenitors
(LSK cells) and HSC (LSKSLAM cells) in the PB (Fig. 3f).
Co-administration of BIO5192 with AMD3100 produced
signiﬁcant increases in total WBC (Supplementary Fig. 2h) but
only a moderate 2.4-fold increase in progenitors and 1.4-fold
increase in HSC compared with BIO5192 alone (Fig. 3f). This is
in stark contrast to the combination of BOP and AMD3100,
which mobilized signiﬁcantly greater numbers of progenitors
and HSC (Fig. 3f) despite inducing similar PB WBC counts
(Supplementary Fig. 2h). These data demonstrate that
concomitant binding to CXCR4 and a4b1 results in mobilization
of predominantly committed WBC but in contrast, co-binding to
a4b1 and a9b1 results in signiﬁcantly increased HSC mobilization.
Inhibiting a9b1 and a4b1 mobilizes functional HSC. To conﬁrm
whether the LSKSLAM and LSK cell phenotype in mobilized PB
was reﬂective of functional HSC and progenitors with long-term
multi-lineage engraftment potential, limiting dilution transplant
analysis was performed using BOP, AMD3100 or the
combination thereof (Fig. 3g). Greater survival was observed in
recipients receiving 30 ml PB mobilized using the combination of
BOP and AMD3100 compared with both BOP and AMD3100
alone (Po0.05) (Fig. 3h). Furthermore, Poisson regression
analysis following limiting dilution transplant revealed PB
mobilized by the BOP and AMD3100 combination resulted in a
greater repopulation frequency of 1 HSC in 23ml PB (95%
conﬁdence interval (CI)¼ 1 HSC in 10 ml to 1 HSC in 51ml)
compared with BOP (1 HSC in 327ml; 95% CI¼ 1 HSC in 150 ml
to 1 HSC in 715ml) or AMD3100 (1 HSC in 351ml; 95% CI¼ 1
HSC in 128ml to 1 HSC in 958 ml) alone, highlighting a greater
than 10-fold improvement to mono-therapy (Po0.005) (Fig. 3i).
These results demonstrate that treatment with BOP either alone
or in combination with AMD3100, mobilizes long-term repo-
pulating HSC and validates ﬂow cytometric monitoring of the
LSKSLAM phenotype as a rapid method for assessing murine
HSC mobilization39.
BOPþAMD3100 is an effective and rapid G-CSF alternative.
Multiple reports have shown G-CSF-dependent mobilization can
be synergistically augmented by co-treatment with cytotoxic
agents, inhibitors of CXCR4 and inhibitors of a4, aL and b1
(refs 9,18,40–42). Consistent with these reports, the treatment of
mice with a single dose of BOP following 4 days of G-CSF resulted
in signiﬁcant synergistic increases in the incidence and the total
numbers of progenitors (LSK) and HSC (LSKSLAM cells) relative
to G-CSF alone (Supplementary Fig. 3a,b and Fig. 4a, respectively).
Importantly, in comparison to mobilization with 4 days of
G-CSF, equivalent numbers of progenitors and equivalent
proportion and number of HSC were mobilized using a single
dose of the combination of BOP and AMD3100 (Fig. 4b
and Supplementary Fig. 3c,d, respectively). In contrast, the
combination of G-CSF and AMD3100 mobilized signiﬁcantly
more progenitors and HSC (Fig. 4b; Supplementary Fig. 3c,d).
However, the greatest number of progenitors and HSC were
mobilized with the combination of 4 days of G-CSF followed by a
single dose of AMD3100 and BOP with a signiﬁcant synergistic
increase compared with G-CSF alone or the combination of
AMD3100 and BOP (Fig. 4b).
To compare the hematopoietic potential of PB mobilized with
multiple doses of G-CSF versus a single dose of BOP and
AMD3100, a competitive long-term reconstitution assay was used
(Fig. 4c). Despite equivalent numbers of HSC being mobilized
following G-CSF and the combination of BOP and AMD3100
(Fig. 4b), signiﬁcantly enhanced short and long-term
multi-lineage engraftment was observed in the PB and BM using
the latter (Fig. 4d,e and Supplementary Fig. 3e,f, respectively).
Furthermore, this signiﬁcantly greater engraftment than was
mathematically expected was maintained in the PB and BM of
secondary transplants (Fig. 4f,g and Supplementary Fig. 3g,h,
respectively). The greater engraftment observed with BOP and
AMD3100-mobilized PB suggests cells with the LSK/LSKSLAM
phenotype mobilized by G-CSF have reduced hematopoietic
potential, which is consistent with previous ﬁndings demonstrat-
ing G-CSF-mobilized LSK cells have signiﬁcantly impaired
engraftment potential relative to native BM LSK43.
BOPþAMD3100 mobilizes human CD34þ HSC in
humanized mice. To determine whether HSC mobilization using
BOP is equivalent in humans, we utilized huNSG mice
(Fig. 5a)24,44. Treatment with a single dose of BOP or AMD3100,
or multiple doses of G-CSF for 4 days alone did not result in a
signiﬁcant increase in PB human WBC (Supplementary Fig. 4) or
human CD34þ stem and progenitors (Fig. 5b). In contrast, a
single dose of BOP in combination with AMD3100 resulted in a
signiﬁcant increase in both human WBC (Supplementary Fig. 4)
and stem and progenitors (Fig. 5b). These data demonstrate
huNSG mice are a useful surrogate model for human HSC
mobilization and demonstrate the promising efﬁcacy of BOP and
AMD3100 for rapid clinical mobilization of human CD34þ cells.
Discussion
Mobilization of HSC and progenitors for PB stem cell transplants
has been clinically adopted for over 30 years. In normal healthy
donors, HSC mobilization is used in over three-quarters of
allogeneic transplants and is predominantly achieved using
standard multi-dose G-CSF over several days. In recent times,
signiﬁcant advances have been made to address the shortcomings
of G-CSF (reviewed in ref. 45) such as the development of CXCR4
antagonists including the FDA-approved AMD3100 (refs 8,9) and
experimental agents such as ALT-1188 (ref. 38) and TG-0054
(ref. 46). For mobilizing healthy donors, identifying novel agents
that effectively, safely, rapidly and selectively mobilize HSC in a
single dose remains clinically important.
HSC are known to express a large number of integrins including
a4b1 and a9b1, which have critical roles in HSC regulation in
BM16. Previous studies have conﬁrmed that the inhibition of
integrin a4b1 and VCAM-1 interactions using neutralizing
antibodies or speciﬁc small molecule inhibitors effectively
mobilize HSC in both mice and primates6,18,19. However, the
role of the related a9b1 in this context is unexplored, in large
part due to the lack of effective anti-a9-blocking antibodies that
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11007 ARTICLE
NATURE COMMUNICATIONS | 7:11007 | DOI: 10.1038/ncomms11007 |www.nature.com/naturecommunications 7
target HSC in vivo or speciﬁc a9-targeting small molecules.
However, given the role a4b1 plays in HSC mobilization and the
fact that a9 and a4 share several ligands including VCAM-1 and
trOpn, a role for a9b1 in HSC mobilization would not be
unexpected. Previously, in vitro studies using a9-blocking
antibodies were found to inhibit CD34þ cell proliferation,
differentiation and adhesion to primary osteoblasts47. In
addition, we demonstrated a9b1/trOpn interactions are potently
chemotactic for HSC and blocking antibodies directed to a9b1
completely inhibits the migration of HSC in vitro16. a9b1 has also
been reported to mediate G-CSF receptor signalling pathways and
contribute to granulopoiesis, as mice lacking a9 have reduced BM
granulocyte precursors as well as impaired neutrophil development
in response to G-CSF48.
In this study, we demonstrate targeting of a9b1/a4b1 using a
single dose of BOP22, induces rapid mobilization of long-term
repopulating HSC through inhibiting integrin-dependent
binding, most likely to trOpn15,16 and VCAM-1 (ref. 17).
Using the ﬂuorescent BOP analogue, R-BC154, we demonstrate
a signiﬁcant proportion of binding to human and murine HSC
occurs through a9b1, whereas binding to lineage-committed cells
is almost exclusively through a4b1. Consequently, inhibition
of a9b1 was found to provide an added advantage to HSC
mobilization yields over inhibition of a4b1 alone as demonstrated
by the signiﬁcantly greater mobilization of HSC and progenitors
using BOP in comparison to the selective a4b1 antagonist
BIO5192; particularly when used in combination with
AMD3100. The reduced synergism in HSC mobilization, but
not WBC mobilization using BIO5192 in combination with
AMD3100 compared with BOP in combination with AMD3100
supports targeting a4 biases towards progenitor mobilization
whereas targeting a9 preferentially mobilizes HSC. The
pronounced increase in AMD3100-mediated mobilization using
BOP relative to BIO5192 suggests the role of integrin a9b1 in HSC
mobilization is magniﬁed with concomitant targeting of CXCR4.
As expected, with the distinct mechanisms of action between
BOP, AMD3100 and G-CSF, the combination of these three
agents resulted in the greatest increase in LSK and LSKSLAM
mobilization when compared with any other combination. Thus,
BOP in combination with G-CSF and AMD3100 is likely to have
signiﬁcant advantages over mobilization using the combination of
G-CSF and AMD3100; although further research is required to
deﬁne the functional capacity of these mobilized blood products.
Currently, the combination of G-CSF and AMD3100 is most
commonly used in autologous transplants, as the combination is
effective and superior to G-CSF alone49. However, in a clinical
context, the use of AMD3100 has advantages compared with
G-CSF, as it directly targets HSC, without altering the function of
the HSC niche, or bone formation3, which is especially important
for the mobilization of normal donors. As a consequence, the use
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of BOP, which also directly targets HSC, will be most
advantageous in combination with AMD3100 as opposed to
BOP alone, as a potential rapid, single dose alternative to G-CSF
for the speciﬁc targeting of HSC in the mobilization of normal
donors for allogeneic transplants.
We have previously shown BM HSC residing within the
endosteal region exhibit greater hematopoietic potential than HSC
isolated from the central medullary region14,29. The functional
characteristics of the endosteal BM have been a topic of great
interest since the concept of a stem cell niche was originally
postulated by Schoﬁeld50. Studies highlighted the endosteal niche
as a hypoxic environment51 where cells such as osteoblasts52,53,
endothelial cells54, perivascular cells12, megakaryocytes55 as well as
their associated ECM proteins are important regulators of HSC
maintenance and function. Herein, we show HSC and progenitors
isolated from the endosteal region express a9b1/a4b1 that are in a
higher afﬁnity, ligand-primed binding conformation relative to
cells from the central compartment. Although the physiological
relevance of this differential integrin activity remains unknown,
these observations are consistent with previous reports that HSC-
dependent binding between trOpn and a4b1 and a9b1 is restricted
to endosteal BM15,16.
One possible explanation for the enhanced priming/activation
of integrins on HSC in endosteal BM are their close proximity to
bone. Bone has a very high mineral content and is the primary
storage site of the inorganic salts of calcium and magnesium as
well as trace metals such as manganese56,57: all of which are
known to play a role in a9b1 and a4b1 adopting the
conformational changes required for ligand binding21,22,58.
Using XFM and quantitative ICP-MS, we demonstrate that
endosteal BM harbours a signiﬁcantly greater concentration of
elemental calcium, magnesium and manganese relative to the
central medullary region. The data strongly suggest this high
divalent metal ion content plays a previously unrecognized role in
differential integrin priming/activation within BM. Although
direct evidence of divalent metal concentration gradients in BM
have not been reported until now, the concept has previously
been invoked to rationalize the preferential localization of HSC
within endosteal BM via recognition of extracellular Ca2þ
through the G protein-coupled calcium-sensing receptor59.
Collectively, these observations further deﬁne the unique nature
of the endosteal niche, the differential inﬂuence it confers in
seemingly phenotypically identical cells and provides validation
for therapeutic targeting of the endosteal stem cell niche for stem
cell therapies60,61.
G-CSF induces the mobilization of BM HSC and progenitors by
causing a ‘cytokine storm’ that results in the cleavage of key
retentive HSC interactions such as CXCR4/SDF-1 (refs 1,2) and
VCAM-1/a4b1. In addition, evidence supports G-CSF and/or
chemotherapy treatment causing a reduction in the homing and
engraftment potential of mobilized PB compared with BM HSC,
which has been suggested to be due to disruption of the HSC
microenvironment62. In addition, previous studies in mice showed
G-CSF-mobilized PB LSK cells have reduced colony-forming
capacity and long-term reconstitution potential compared with
their untreated BM counterparts43,63. Furthermore, in healthy
human donors mobilized using G-CSF, apheresis products
contained reduced frequencies of NOD/SCID repopulating cells
compared with AMD3100-mobilized PB from the same donors64.
The current study adds to these ﬁndings, demonstrating G-CSF
mobilizes proportionally more phenotypic LSK progenitors than
LSKSLAM HSC and following a transplant of equal volumes of
mobilized PB, the use of G-CSF resulted in a reduced capacity to
sustain long-term hematopoiesis relative to mobilized PB using the
combination of BOP and AMD3100. Together, these results
support previous ﬁndings that G-CSF-mobilized HSC and
progenitors have reduced in vitro and in vivo capacity relative to
their well-deﬁned BM counterparts in steady state43.
Variability observed with HSC mobilization following G-CSF is
well documented, both within patients and in different mouse
strains65. For example, BALB/c mice are effectively mobilized by
G-CSF, whereas C57BL/6 mice are considered ‘poor mobilizers’39.
Although the NODSCIDIL2Rg / mouse model has routinely
and successfully been used to assess the hematopoietic potential
of human HSC and progenitors24, previous studies have not
assessed the ability of G-CSF to effectively mobilize CD34þ cells
in humanized NODSCIDIL2Rg / mice. The current data
demonstrate signiﬁcant impairment. In contrast, the combination
of BOP and AMD3100 resulted in signiﬁcant mobilization of
human CD34þ cells, suggesting the use of this strategy may be
effective in clinical mobilization of human donors.
In summary, we demonstrate that a single dose of BOP, a small
molecule targeting a4b1 and a9b1 integrins, effectively and rapidly
mobilizes HSC with long-term multi-lineage engraftment
potential, identifying a previously unrecognized role for a9b1 in
HSC mobilization. When used in combination with CXCR4
inhibitors such as AMD3100, signiﬁcantly enhanced mobilization
of long-term repopulating HSC was observed relative to G-CSF.
The efﬁcacy of HSC mobilization using the BOP and AMD3100
combination was recapitulated in the mobilization of CD34þ
cells in humanized NODSCIDIL2Rg / mice. Using the related
ﬂuorescently labelled integrin antagonist R-BC154, we show that
this class of compounds bind murine and human HSC and
progenitors via endogenously activated/primed a4b1 and a9b1
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within the endosteal niche. Furthermore, we show that the
majority of R-BC154/BOP binding to human HSC occurs via
a9b1, which is absent on lineage-committed cells. These results
highlight an effective and convenient strategy of therapeutically
targeting endosteal HSC which address many of the shortcomings
associated with G-CSF and paves the way for the development of
additional selective small molecule a9b1 integrin antagonists for
preferential HSC mobilization.
Methods
Compounds and reagents. R-BC154 and BOP were synthesized according to
previously published methods21,22. BIO5192 (Tocris Bioscience), AMD3100
(octahydrochloride hydrate salt) (Sigma-Aldrich) and human G-CSF (Filgrastim,
Amgen, Thousand Oaks, CA, USA) were used without further puriﬁcation.
For in vivo experiments, lyophilized powders of R-BC154 and BOP sodium salts
were dissolved in 10% hydroxypropyl-b-cyclodextrin (HPbCD) in saline (w/v).
A stock solution of BIO5192 in DMSO (10mgml 1) was diluted to 0.1mgml 1
in 10% HPbCD/saline immediately before use.
Mice. C57BL/6, red ﬂuorescent protein (RFP), green ﬂuorescent protein (GFP),
a4ﬂox/ﬂoxa9ﬂox/ﬂox vav-cre, NODSCIDIL2Rg / (NSG) mice were bred at Monash
Animal Services (Monash University, Clayton, Australia). Conditional a4ﬂox/ﬂox-
a9ﬂox/ﬂox mice were initially generated by cross-breeding a4ﬂox/ﬂox mice with a9ﬂox/ﬂox
mice and vav-cre mice. For transplants, irradiation was given in a split dose
(5.25Gy each) 6 h apart, 24 h before transplant for C57BL/6 mice and in a single
dose (2.75Gy) 5 h before transplant for NSG mice and a total of 2 105 irradiated
(15Gy) C57BL/6 BM cells or 2 106 irradiated (15Gy) umbilical CB MNC given
as support cells to each recipient, respectively. All experiments were approved by
Monash Animal Services Ethics Committee.
Umbilical CB and human BM. Umbilical CB and human BM were obtained
from the Mercy Hospital for Women (East Melbourne, Australia) and patients
undergoing hip replacement at St Vincent’s Public Hospital or St Vincent’s Private
Hospital (East Melbourne, Australia), respectively15. All experiments were
following informed consent and approved by the ethics committee of each
respective hospital and written consent was obtained from all subjects.
Human CD34þ cell isolation. Low-density MNC were isolated from human
CB or BM by discontinuous density centrifugation using Ficoll-Hypaque
(1.077 gml 1, Pharmacia Biotech, Sweden). Lineage-negative cells were then
isolated using mouse-anti-human CD3, CD11b, CD14, CD16, CD20, CD24
and CD235a (BD, Franklin Lakes, NJ, USA), and Dynal sheep anti-mouse
immunoglobulin G (IgG) beads (Invitrogen, Carlsbad, CA, USA). Cells were
then stained with CD34-FITC and CD38-PE (BD, Franklin Lakes, NJ, USA) for
subsequent ﬂuorescence-activated cell separation15,16. All antibodies were used at
optimal pre-titred concentrations (Supplementary Table 2).
Murine hematopoietic cell isolation. For the isolation of murine central marrow,
the ends of femurs, tibias and iliac crests were removed and the bones ﬂushed using
a 21- or 23-gauge needle. For the isolation of endosteal cells, the marrow-depleted
bones and the bone ends were ground in a mortar and pestle. The bone fragments
were washed, incubated in 3mgml 1 Collagenase I (Roche, Basel, Switzerland)
and 4mgml 1 Dispase II (Worthington, Lakewood, NJ), in phosphate-buffered
saline (PBS; 310mOsm) in a shaking incubator (37 C; 250 r.p.m. for 5min), then
washed by vigorously shaking66. RBC in collected PB were lysed using NH4Cl lysis
buffer for 5min at room temperature.
Generation of humanized NSG mice. Humanized NSG mice were generated by
transplanting sorted CB CD34þ cells (1.5–2.0 105) with 2 106 irradiated
(15Gy) CB MNC. After 4 weeks, PB was assessed for the proportion of human
CD45þ cells using anti-huCD45 and muCD45 antibodies.
Cell lines. LN18 and Chinese hamster ovary (CHO) cells were obtained from the
ATCC. a4b1 and a9b1 expressing human LN18 cells were maintained in DMEM
supplemented with 2mM L-glutamine and 10% fetal bovine serum (FBS)21. CHO
cells overexpressing murine a9 and a4 were generated by retroviral transduction
using pMSCV-ma9-IRES-eGFP and pMSCV-ma4-IRES-eGFP16, and maintained
in DMEM/F-12 medium supplemented with 2mM L-glutamine and 10% FBS.
Flow cytometry. Flow cytometric analysis was performed using an LSR II (BD
Biosciences)16. R-BC154 was detected at either 582 or 610 nm and excited with
the yellow-green laser (561 nm). For BM and PB analysis cells were analysed at
10–20,000 cells per s. Cell sorting was performed on a Cytopeia Inﬂux (BD)16.
All sorts were re-analysed with a purity of 498%.
Antibody cocktails. For analysis of human WBC from CB MNC or BM and PB
from huNSG mice, cells were processed as described above and immunolabelled
with anti-huCD34 and anti-huCD38 antibodies. For analysis of huNSG mice,
anti-huCD45 and anti-muCD45 antibodies were also included. For analysis of
murine progenitor cells (LSK; LineageSca-1þ c-kitþ ) and HSC (LSKSLAM;
LSKCD150þCD48 ), BM and PB cells were immunolabelled with a lineage
cocktail (anti-B220, anti-CD3, anti-Gr-1, anti-Mac-1), anti-Sca-1, anti-c-kit,
anti-CD48 and anti-CD150 antibodies. For lineage analysis, cells were stained with
anti-CD3, anti-B220, anti-Mac-1 and anti-Gr-1 antibodies. A full list of antibodies
and their working concentrations used in this work is detailed in Supplementary
Tables 1 and 2.
Expression of a4 and a9b1 integrins on human HSC. The expression of human
a4 (CD49d) and a9b1 on human HSC from CD34þ enriched human BM cells, BM
from huNSG mice and CB MNC CD34þ cells were assessed by the sequential
labelling of cells with puriﬁed mouse-anti-human a9b1, goat-anti-mouse-AF647
followed by a cocktail of mouse-anti-huCD49d-PECy7, anti-huCD34-FITC and
anti-huCD38-BV421. Matching mouse IgG1 isotypes were used as controls.
In vitro and in vivo R-BC154 binding. For in vitro labelling experiments, up to
5 106 BM cells from C57 mice, conditional a4 / /a9 / vav-cre mice, huNSG,
CB MNC and sorted CD34þ cells, were treated with R-BC154 (up to 300 nM) in
PBS (0.5% BSA) or TBS (0.5% BSA) containing no exogenous cations or 1mM
CaCl2/MgCl2. In vitro labelling experiments were not conducted using Mn2þ in
the binding buffer as BIO5192 has previously been shown to exhibit low levels of
binding to a9b1 under these conditions23. R-BC154 staining in the presence of
10mM EDTA was used as the negative control. For in vivo experiments, C57BL/6
and huNSG mice received subcutaneous injections of R-BC154 (5–10mg kg 1) at
100 ml per 10 gm mouse weight and PB and BM analysed as described above. For
competitive displacement of in situ-bound R-BC154, WBM cells were treated with
500 nM BOP in PBS containing 0.5% BSA and 1mM CaCl2/MgCl2 for 45min at
37 C before ﬂow cytometric analysis.
Determination of a9b1 contribution to R-BC154 binding. For the assessment of
a9b1 contribution to R-BC154 binding, human and murine cells were stained with
R-BC154 (100 nM) in the absence of competing antagonist or in the presence of
excess amounts of the selective a4b1 antagonist BIO5192 (1mM) or dual a4b1/a9b1
antagonist BOP (1mM) in PBS containing 0.5% BSA and 1mM CaCl2/MgCl2 at
0 C for 30min. Cells were washed, immunolabelled as described above and
analysed by ﬂow cytometry. The contribution of a9b1 binding was calculated by
measuring the difference in MFI between R-BC154þBIO5192 and R-BC154þ
BOP and expressed as a % of R-BC154 alone. Transduced LN18 cells and CHO
cells incubated under identical conditions were used as controls, which
conﬁrmed BIO5192 inhibited 495% of R-BC154 binding to a4b1 but did not
inhibit binding to a9b1. In contrast, BOP inhibited 495% of R-BC154 binding to
both a4b1 and a9b1. For single-cell correlation analysis, scaled ﬂuorescence
intensity values for both R-BC154 binding to a9b1 in the presence of BIO5192
(to prevent any binding to a4b1) and a9b1 parameters were determined for
individual CD34þCD38 cells using FlowJo X. Linear regression analysis was
performed using GraphPad Prism.
Measurement of calcium gradients in BM. Sample preparation. C57BL/6 mice
were perfusion ﬁxed with 4% PFA, femurs excised and inﬁltrated and embedded in
methacrylate as per the manufacturer’s instructions (JB-4 Plus embedding kit,
ProSciTech, Australia). Sections (15mm) of diaphyseal BM were cut using a
tungsten carbide knife and transferred onto 10 10mm silicon nitride (Si)
windows (4mm2 window size and 2 mm thickness; Melbourne Centre for
Nanofabrication, Australia). Sections were dried and stored in a dehumidiﬁed
environment before XFM analysis.
X-ray ﬂuorescence microscopy. Specimens were analysed using the XFM
beamline at the Australian Synchrotron67. Unlike full-ﬁeld imaging common in
optical microscopy, XFM is a scanning probe technique where the sample is
translated through a focused beam of incident radiation. A beam of 12.7 keV
X-rays was focused to a spot of 2.5 mm (full-width at half-maximum of the
intensity) using a Kirkpatrick-Baez mirror pair. Using these settings, the intensity
proﬁle at the focal plane is a Gaussian distribution68 with a s.d. of 1.06mm. The
proportion of incident light which would illuminate from bone at a distance of
20 mm is determined as B10 81, excluding any possible signal contamination
from the high levels of bone Ca. Nevertheless, analysis of calcium content directly
at the bone/BM interface (B0–20 mm from bone; shaded area in Fig. 2h) was
avoided and quantitation of calcium was restricted to 420 mm from the bone
surface. We have previously arbitrarily deﬁned the interface between endosteal and
central BM as B12 cell diameters (or B100 mm) from the bone surface13.
The X-ray energy was chosen to induce K-shell ionization of elements with
atomic numbers below 34 (ZoSe). The specimen was continuously scanned
through the focus using a virtual pixel size of 2 mm, well matched to the beam
proﬁle. Full x-ray ﬂuorescence (XRF) spectral images were obtained at each pixel
using an effective dwell time of 31.25ms. The low-latency, large solid angle
384-channel Maia XRF detector was positioned in the back-scatter geometry and
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the resulting elemental maps ranged up to 142,129 pixels in size. Quantiﬁcation
using the Maia system is based on a fundamental parameter approach able to
operate in real time and has no requirement for explicit per-element
calibration69,70. Two single element foils, Mn and Pt (Micromatter, Canada), were
scanned during the experiment and provided sufﬁcient information for use as
experimental references to establish elemental quantitation. Deconvolution of the
X-ray ﬂuorescence spectra was performed using GeoPIXE v6.3 (ref. 69; CSIRO,
Australia) and calibrated using the metal foil measurements. Images were analysed
using ImageJ and the relative calcium content quantiﬁed by measuring the pixel
intensities from lines of interest (n¼ 10) extending from the endosteum towards
the central vein.
ICP-MS analysis of BM calcium, magnesium and manganese. Femurs, tibias
and iliac crests (3 mice pooled per group, n¼ 3) were excised, the epi- and meta-
physeal regions removed and the bones ﬂushed with a total of 1.2ml of cation-free
PBS to obtain central BM cellular fractions. The endosteal cellular fraction was
harvested by gently grinding the ﬂushed bones, and epi- and metaphyseal fragments
in a small mortar and pestle using a total of 1.2ml of PBS. This level of grinding has
previously been demonstrated not to impact cell viability or function14,29.
The extracellular fractions were collected in the supernatant following cell
centrifugation. To control for the grinding ‘selectively contaminating’ the eBM
samples, bones were ﬂushed in PBS to remove central marrow cells, then ﬂushed
and incubated in 3mg per ml collagenase I and 4mg per ml dispase II to release the
residual-bound cells and proteins as per routine endosteal marrow isolation
procedure, followed by further ﬂushing with PBS. The empty bones were then
vigorously ground in 0.5ml PBS and the released cation concentrations were
measured. This grinding was signiﬁcantly more intensive than that which is
normally used to release endosteal cells.
To separate the cell-associated cations into membrane-associated and
intracellular fractions, half of the cell pellets were treated with 10mM EDTA to
remove any membrane-associated cations. All cell pellets were then frozen at
 80 C, freeze dried and digested with 50 ml of concentrated nitric acid 65%
(Suprapur, Merck) overnight at room temperature followed by heating at 90 C for
20min to complete the digestion. The reduced volume after digestion was B35 ml
and each sample was made up to 1ml by the addition of 965 ml of 1% (v/v) of nitric
acid diluent. The central and endosteal supernatants were centrifuged at 10,000g to
remove any residual cellular debris and a 100ml aliquot diluted 10-fold with 1% (v/
v) nitric acid diluent. ICP-MS measurements were obtained on an Agilent 7700
series ICP-MS instrument under routine multi-element operating conditions using
a Helium Reaction Gas Cell. The instrument was calibrated using 0, 5, 10, 50, 100
and 500 p.p.b. of certiﬁed multi- element ICP-MS standard calibration solutions
(ICP-MS-CAL2-1, ICP-MS-CAL-3 and ICP-MS-CAL-4, Accustandard) for a range
of elements. A certiﬁed internal standard solution containing 200 p.p.b. of Yttrium
(Y89) was used as an internal control (ICP-MS-IS-MIX1-1, Accustandard). Results
were calculated as micrograms of metal per gram of wet weight (mg g 1) or
mmol l 1 for the cellular fraction and extracellular fraction, respectively, and then
normalized to micrograms of metal per two hindlimbs or cell number, respectively.
HSC mobilization. Mice received subcutaneous injections at 100 ml per 10 gm body
weight of: a single injection of BOP (up to 15mg kg 1) for various timeframes, a
single BIO5192 injection at 1mg kg 1 for 1 h, a single AMD3100 injection at
3mg kg 1 for 1 h (mice also receiving BOP or BIO5192 were injected with a single
dose of BOP or BIO5192 1 h before harvest), or G-CSF at 250mg kg 1 twice daily
(500 mg kg 1 day 1), 6–8 h apart for 4 consecutive days (mice also receiving BOP
and/or AMD3100 were injected with a single dose of BOP and/or AMD3100 1 h
before harvest). Control mice received an equivalent volume of saline or 10%
HPbCD/saline where appropriate.
Long-term transplant assays. Limiting dilution transplants. RFP mice were
treated with either BOP, AMD3100 or a combination of BOP and AMD3100 and
PB harvested after 1 h. Equal volumes of PB from each donor from each treatment
group was pooled, red cells lysed and WBC resuspended in 200 ml PBS per reci-
pient. Irradiated WBM ﬁller cells were added and then resuspended in PBS for
transplantation by tail vein injection. Multi-lineage RFP engraftment was assessed
at 6, 12 and 20 weeks post transplant.
Competitive limiting dilution transplants. RFP and GFP mice were treated with
BOPþAMD3100 and G-CSF, respectively, before PB was harvested and equivalent
blood volumes pooled within each treatment group. Red cells were lysed and equal
volumes (based on original pre-lysed blood volume) of RFP and GFP PB were
transplanted with irradiated WBM ﬁller cells in 200ml per recipient. RFP and GFP
engraftment assessed after 6, 12 and 20 weeks. After 20 weeks WBM cells (1/10th of
a femur) from individual primary recipients (n¼ 5) were transplanted into
irradiated C57 secondary recipients (n¼ 4 per primary recipient) and assessed for
multi-lineage engraftment after 6, 12 and 20 weeks. Greater than 1% B220þ ,
CD3þ and Gr1Mac1þ donor engraftment was considered multi-lineage.
Statistical analysis. Data were analysed using unpaired or paired student’s t-test
or one-way analysis of variance where appropriate. If the difference between group
means was statistically signiﬁcant, post hoc analysis using the Tukey approach was
performed. For determination of stem cell repopulation frequency, Poisson
analysis using L-CALC software (Stem Cell Technologies) was used. A log-rank
(Mantel–Cox) test was used to compare survival curves. Po0.05 was considered
signiﬁcant.
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